US03209R1032
US03209R1032
Amphastar Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 719.887.000 | 731.967.000 | 1.7% |
| Cost of Revenue | 363.830.000 | 358.112.000 | 1.6% |
| Gross Profit | 356.057.000 | 373.855.000 | 4.8% |
| 215.654.000 | 168.436.000 | 28.0% | |
| Operating Income | 140.403.000 | 205.419.000 | 31.7% |
| Pretax Income | 123.624.000 | 189.764.000 | 34.9% |
| Net Income Common Stockholders | 98.094.000 | 159.519.000 | 38.5% |
| -- | -- | -- | |
| -- | -- | -- |